Back to Trades
Total Value
$NaN
Filing Date
Mar 27, 2026
1 transactions
Trade Summary
On Mar 18, 2026, Rubin Eyal, Chief Financial Officer, reported $NaN of Nasus Pharma Ltd (NSRX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $NaN. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Nasus Pharma Ltd
- Ticker Symbol
- NSRX
- CIK
- 0002029039
Insider Information
- Name
- Rubin Eyal
- Role
- Chief Financial Officer
Filing Details
- Filing Date
- Mar 27, 2026
- Transaction Date
- Mar 18, 2026
- Accession Number
- 0001493152-26-013399
- Form Type
- 3
Want live alerts when Rubin Eyal trades again?
Download Insider Trades to track NSRX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)Options to purchase 85,648 ordinary shares of the Issuer, no par value ("Ordinary Shares") were granted on November 20, 2025 with 8.3333% of the total grant vesting 457 days following November 20, 2025, and the remaining 91.6667% vesting in equal quarterly installments of 8.3333% thereafter. As of March 18, 2026, 85,648 options remain outstanding, none of which are vested, at an exercise price of $7.56 per share, expiring November 20, 2035.
- (F2)Options to purchase 40,549 Ordinary Shares were granted on November 20, 2025, with 100% of the total grant vesting on November 20, 2026. As of March 18, 2026, 40,549 options remain outstanding, none of which are vested, at an exercise price of $7.56 per share, expiring November 20, 2035.